VivoSeq
Other

ADPKD

0

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

ADPKD is an early-stage landscape with 0 programs across 4 companies. The most active players are Otsuka, Mario Negri Institute for Pharmacological Research, Palladio Biosciences.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Otsuka logo

Otsuka

0 programs

PreclinicalMario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

0 programs

PreclinicalP

Palladio Biosciences

0 programs

PreclinicalK

Korea Otsuka Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed6 · 60%
Terminated2 · 20%
Active, not recruiting1 · 10%
Recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT06582875·126 enrolled
Study of Tamibarotene in Patients With ADPKD
Active, not recruiting·RRege Nephro Co., Ltd.·Phase 2·NCT06289998·70 enrolled
Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD
Completed·RRegional Hospital Holstebro·Phase 3·NCT03803124·20 enrolled
Tolvaptan-Octreotide LAR Combination in ADPKD
Completed·Mario Negri Institute for Pharmacological Research logoMario Negri Institute for Pharmacological Research·Phase 2·NCT03541447·20 enrolled
Tolvaptan Extension Study in Participants With ADPKD
Completed·Otsuka logoOtsuka·Phase 3·NCT01214421·1,083 enrolled
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
Completed·Otsuka logoOtsuka·N/A·NCT02847624·1,802 enrolled
Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
Completed·Otsuka logoOtsuka·Phase 2·NCT01210560·25 enrolled
Samsca PMS in ADPKD Patients
Completed·KKorea Otsuka Pharmaceutical Co., Ltd.·N/A·NCT03406286·2,067 enrolled
Everolimus on CKD Progression in ADPKD Patients
Terminated·—·Phase 2/3·NCT01009957·71 enrolled
Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303
Terminated·PPalladio Biosciences·Phase 3·NCT05208866·1 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)